Open Market Insiders Trades - Sells only
This list includes insiders general transaction with codes filed in Form 4 from SEC:
- S - Open market or private sale of non-derivative or derivative security
- V - Transaction voluntarily reported earlier than required
| Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
|---|---|---|---|---|---|---|
|
CLXT
|
Gerhard Prante
Director |
SELL
Open market or private sale
|
Direct | 1,150 Reduced 2.29% |
$3,611
$3.14 p/Share
|
Jan 06
2025 |
|
CLAQW
|
John W Gibson Jr
Interim CEO |
SELL
Open market or private sale
|
Direct | 3,190 Reduced 3.26% |
$19,235
$6.03 p/Share
|
Jan 06
2025 |
|
PINC
|
Helen M Boudreau |
SELL
Open market or private sale
|
Direct | 2,500 Reduced 10.79% |
$53,550
$21.42 p/Share
|
Jan 06
2025 |
|
NOC
|
Mark A Welsh Iii
Director |
SELL
Open market or private sale
|
Direct | 33 Reduced 0.79% |
$15,121
$458.24 p/Share
|
Jan 06
2025 |
|
VICR
|
Andrew D'Amico
Director |
SELL
Open market or private sale
|
Direct | 2,000 Reduced 100.0% |
$103,840
$51.92 p/Share
|
Jan 06
2025 |
|
NMAI
|
Saba Capital Management, L.P.
> 10% Shareholder |
SELL
Open market or private sale
|
Indirect | 32,422 Reduced 0.0% |
$395,872
$12.21 p/Share
|
Jan 06
2025 |
|
ACLX
|
Rami Elghandour |
SELL
Open market or private sale
|
Direct | 13,776 Reduced 8.45% |
$1,063,093
$77.17 p/Share
|
Jan 06
2025 |
|
ACLX
|
Christopher Heery
CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct | 3,061 Reduced 8.62% |
$236,217
$77.17 p/Share
|
Jan 06
2025 |
|
ACLX
|
Christopher Heery
CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct | 3,061 Reduced 8.62% |
$236,217
$77.17 p/Share
|
Jan 06
2025 |
|
EDR
|
William K. Fullerton
Global Controller and CAO |
SELL
Open market or private sale
|
Direct | 6,875 Reduced 11.43% |
$214,293
$31.17 p/Share
|
Jan 06
2025 |
|
ACLX
|
Michelle Gilson
CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct | 5,102 Reduced 15.31% |
$393,721
$77.17 p/Share
|
Jan 06
2025 |
|
BAND
|
David A. Morken
Chairman & CEO |
SELL
Open market or private sale
|
Direct | 2,777 Reduced 2.47% |
$48,292
$17.39 p/Share
|
Jan 06
2025 |
|
BAND
|
Rebecca Bottorff
Chief People Officer |
SELL
Open market or private sale
|
Direct | 532 Reduced 1.07% |
$9,251
$17.39 p/Share
|
Jan 06
2025 |
|
BAND
|
Kade Ross
Chief Information Officer |
SELL
Open market or private sale
|
Direct | 440 Reduced 0.83% |
$7,651
$17.39 p/Share
|
Jan 06
2025 |
|
BAND
|
Devin M Krupka
Controller, PAO |
SELL
Open market or private sale
|
Direct | 120 Reduced 1.04% |
$2,086
$17.39 p/Share
|
Jan 06
2025 |
|
BAND
|
Daryl Raiford
Chief Financial Officer |
SELL
Open market or private sale
|
Direct | 1,305 Reduced 1.33% |
$22,693
$17.39 p/Share
|
Jan 06
2025 |
|
BAND
|
Richard Brandon Asbill
General Counsel |
SELL
Open market or private sale
|
Direct | 822 Reduced 1.86% |
$14,294
$17.39 p/Share
|
Jan 06
2025 |
|
RLAY
|
Peter Rahmer |
SELL
Open market or private sale
|
Direct | 16,576 Reduced 5.1% |
$73,763
$4.45 p/Share
|
Jan 06
2025 |
|
ZYME
|
Paul Andrew Moore
Chief Scientific Officer |
SELL
Open market or private sale
|
Direct | 21,200 Reduced 47.61% |
$316,304
$14.92 p/Share
|
Jan 06
2025 |
|
ZYME
|
Kenneth Galbraith
Chair & CEO |
SELL
Open market or private sale
|
Direct | 57,291 Reduced 41.49% |
$854,781
$14.92 p/Share
|
Jan 06
2025 |
|
ZIP
|
Ian H. Siegel
CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Indirect | 9,722 Reduced 0.0% |
$70,678
$7.27 p/Share
|
Jan 06
2025 |
|
AGYS
|
Kaufman 2012 Descendants Trust, David N. Smith, Trustee |
SELL
Open market or private sale
|
Direct | 7,500 Reduced 2.32% |
$977,550
$130.34 p/Share
|
Jan 06
2025 |
|
VKTX
|
Greg Zante
Chief Financial Officer |
SELL
Open market or private sale
|
Direct | 50,309 Reduced 23.34% |
$2,163,287
$43.0 p/Share
|
Jan 06
2025 |
|
VKTX
|
Marianna Mancini
Chief Operating Officer |
SELL
Open market or private sale
|
Direct | 54,215 Reduced 12.66% |
$2,331,245
$43.0 p/Share
|
Jan 06
2025 |
|
VKTX
|
Brian Lian
President & CEO |
SELL
Open market or private sale
|
Direct | 194,490 Reduced 7.59% |
$8,363,070
$43.0 p/Share
|
Jan 06
2025 |
|
ZYME
|
Jeffrey T L Smith
EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct | 11,110 Reduced 55.55% |
$165,761
$14.92 p/Share
|
Jan 06
2025 |
|
SKWD
|
Sandip A Kapadia
EVP, CHIEF ACTUARY |
SELL
Open market or private sale
|
Direct | 908 Reduced 8.05% |
$42,657
$46.98 p/Share
|
Jan 06
2025 |
|
SKWD
|
Andrew S Robinson
CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct | 177 Reduced 0.28% |
$8,338
$47.11 p/Share
|
Jan 06
2025 |
|
TERN
|
Jill M. Quigley |
SELL
Open market or private sale
|
Direct | 8,760 Reduced 100.0% |
$50,720
$5.79 p/Share
|
Jan 06
2025 |
|
BCYC
|
Travis Alvin Thompson
CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct | 2,686 Reduced 7.71% |
$40,290
$15.0 p/Share
|
Jan 06
2025 |
|
TERN
|
Mark J. Vignola
Chief Financial Officer |
SELL
Open market or private sale
|
Direct | 9,059 Reduced 10.81% |
$52,542
$5.8 p/Share
|
Jan 06
2025 |
|
SKYH
|
Boston Omaha Corp
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 10,029 Reduced 0.09% |
$116,837
$11.65 p/Share
|
Jan 06
2025 |
|
SKWD
|
Thomas N Schmitt
CHIEF PEOPLE & ADMIN. OFFICER |
SELL
Open market or private sale
|
Direct | 546 Reduced 5.06% |
$25,580
$46.85 p/Share
|
Jan 06
2025 |
|
SKWD
|
Leslie Shaunty
GENERAL COUNSEL & SECRETARY |
SELL
Open market or private sale
|
Direct | 344 Reduced 1.66% |
$16,192
$47.07 p/Share
|
Jan 06
2025 |
|
BRDG
|
Garrett Behling
Chief Accounting Officer |
SELL
Open market or private sale
|
Direct | 762 Reduced 1.65% |
$6,332
$8.31 p/Share
|
Jan 06
2025 |
|
TVTX
|
Jula Inrig
CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct | 440 Reduced 0.73% |
$8,254
$18.76 p/Share
|
Jan 06
2025 |
|
BRDG
|
Dean Allara
Vice Chairman |
SELL
Open market or private sale
|
Direct | 10,877 Reduced 1.62% |
$90,387
$8.31 p/Share
|
Jan 06
2025 |
|
BRDG
|
Jonathan Slager
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 11,883 Reduced 1.25% |
$98,747
$8.31 p/Share
|
Jan 06
2025 |
|
BRDG
|
Adam O'Farrell
Chief Operating Officer |
SELL
Open market or private sale
|
Direct | 6,935 Reduced 1.27% |
$57,629
$8.31 p/Share
|
Jan 06
2025 |
|
BRDG
|
Robert Randolph Morse
Executive Chairman |
SELL
Open market or private sale
|
Direct | 47,252 Reduced 1.47% |
$392,664
$8.31 p/Share
|
Jan 06
2025 |
|
BRDG
|
Katherine Elsnab
Chief Financial Officer |
SELL
Open market or private sale
|
Direct | 3,206 Reduced 1.07% |
$26,641
$8.31 p/Share
|
Jan 06
2025 |
|
PANW
|
Nikesh Arora
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 176,242 Reduced 13.96% |
$31,758,808
$180.2 p/Share
|
Jan 06
2025 |
|
PCRX
|
Jonathan Slonin
Chief Medical Officer |
SELL
Open market or private sale
|
Direct | 879 Reduced 0.93% |
$16,173
$18.4 p/Share
|
Jan 06
2025 |
|
FNKO
|
Andrew David Oddie
CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct | 358 Reduced 1.74% |
$5,012
$14.0 p/Share
|
Jan 06
2025 |
|
KYMR
|
Ellen Chiniara
Chief Legal Officer |
SELL
Open market or private sale
|
Direct | 3,129 Reduced 5.4% |
$130,635
$41.75 p/Share
|
Jan 06
2025 |
|
RM
|
Forager Fund, L.P. |
SELL
Open market or private sale
|
Direct | 6,265 Reduced 0.59% |
$209,626
$33.46 p/Share
|
Jan 06
2025 |
|
SEMR
|
Dmitry Melnikov
Director |
SELL
Open market or private sale
|
Indirect | 33,705 Reduced 0.0% |
$399,741
$11.86 p/Share
|
Jan 06
2025 |
|
BBAI
|
Amanda Long
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 66,140 Reduced 2.63% |
$297,630
$4.5 p/Share
|
Jan 06
2025 |
|
HGTY
|
Robert I Kauffman
Director |
SELL
Open market or private sale
|
Indirect | 6,111 Reduced 0.0% |
$59,032
$9.66 p/Share
|
Jan 06
2025 |
|
GHC
|
Marcel A. Snyman
VP-Chief Accounting Officer |
SELL
Open market or private sale
|
Direct | 159 Reduced 26.46% |
$140,126
$881.3 p/Share
|
Jan 06
2025 |